Current evidence on the use of the adalimumab biosimilar SB5 (ImraldiTM): a multidisciplinary perspective
This review provides an overview of data from trials and real-world studies available for SB5 (ImraldiTM) across three main therapeutic areas: rheumatology, gastroenterology, and dermatology. Areas covered A literature search for publications on data for SB5 efficacy/effectiveness, safety, and immun...
| Autores: | , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2021 |
| País: | España |
| Institución: | Universidad Autónoma de Madrid |
| Repositorio: | Biblos-e Archivo. Repositorio Institucional de la UAM |
| Idioma: | inglés |
| OAI Identifier: | oai:repositorio.uam.es:10486/711198 |
| Acceso en línea: | http://hdl.handle.net/10486/711198 https://dx.doi.org/10.1080/14712598.2022.2012146 |
| Access Level: | acceso abierto |
| Palabra clave: | biosimilar adalimumab anti-TNF SB5 Imraldi dermatology gastroenterology rheumatology multidisciplinary Medicina |
| Sumario: | This review provides an overview of data from trials and real-world studies available for SB5 (ImraldiTM) across three main therapeutic areas: rheumatology, gastroenterology, and dermatology. Areas covered A literature search for publications on data for SB5 efficacy/effectiveness, safety, and immunogenicity was undertaken. Expert opinion, Evidence derived from clinical studies suggest that the biosimilar SB5 is a safe and effective alternative to reference adalimumab. Considering that patients suffering from immune-mediated inflammatory diseases such as inflammatory arthritis, inflammatory bowel disease and psoriasis often require long-term biologic treatment, biosimilar medicines (such as SB5) can reduce healthcare costs while increasing access to effective treatments |
|---|